Tudor Investment Corp’s Aclaris Therapeutics ACRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-33,183
Closed -$38.2K 2955
2024
Q3
$38.2K Hold
33,183
﹤0.01% 2624
2024
Q2
$36.5K Hold
33,183
﹤0.01% 2237
2024
Q1
$41.1K Hold
33,183
﹤0.01% 2121
2023
Q4
$34.8K Hold
33,183
﹤0.01% 2275
2023
Q3
$227K Buy
33,183
+1
+0% +$9 ﹤0.01% 2034
2023
Q2
$344K Buy
33,182
+2,038
+7% +$18.4K ﹤0.01% 1922
2023
Q1
$252K Buy
+31,144
New +$395K ﹤0.01% 2046
2022
Q3
Sell
-12,090
Closed -$169K 2261
2022
Q2
$169K Buy
+12,090
New +$169K ﹤0.01% 1861
2021
Q4
Sell
-10,539
Closed -$190K 2317
2021
Q3
$190K Buy
+10,539
New +$169K ﹤0.01% 2318
2020
Q4
Sell
-20,750
Closed -$53K 1305
2020
Q3
$53K Sell
20,750
-37,976
-65% -$85K ﹤0.01% 1211
2020
Q2
$95K Hold
58,726
﹤0.01% 1089
2020
Q1
$61K Sell
58,726
-200
-0.3% -$272 0.01% 960
2019
Q4
$111K Hold
58,926
0.01% 1047
2019
Q3
$64K Buy
+58,926
New +$83.6K ﹤0.01% 1023
2019
Q1
Sell
-12,906
Closed -$95K 1080
2018
Q4
$95K Buy
+12,906
New +$133K ﹤0.01% 928
2018
Q1
Sell
-12,296
Closed -$303K 973
2017
Q4
$303K Buy
+12,296
New +$299K 0.01% 794

Other funds holding ACRS

Tudor Investment Corp's ACRS Position: Q4 2024 in Review

Tudor Investment Corp sold out of Aclaris Therapeutics (ACRS) in Q4 2024, closing a stake of 33,183 shares — an estimated $38.2K sold.

Tudor Investment Corp first reported a position in ACRS in Q4 2017 and held it in 16 quarters. The position peaked at $344K in Q2 2023. 98 funds tracked by Wall St. Rank hold ACRS as of Q4 2024.

  • Tudor Investment Corp reported no remaining Aclaris Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Tudor Investment Corp sold 33,183 Aclaris Therapeutics shares in Q4 2024, an estimated $38.2K.
  • Tudor Investment Corp first reported a position in Aclaris Therapeutics in Q4 2017 and held it in 16 quarters.
  • Tudor Investment Corp's Aclaris Therapeutics position peaked at $344K in Q2 2023.
  • 98 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2024.

Based on Tudor Investment Corp's 13F filing for Q4 2024, filed 14 Feb 2025.